Latest News and Press Releases

Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.

TORONTO, ON, May 11, 2026 (GLOBE NEWSWIRE) -- Thousands of Canadians will come together this May 31st for MS Canada’s annual MS Walk, a powerful, community-driven event dedicated to...

Trethera to present optic neuritis research, highlighting TRE-515, a first-in-class oral inhibitor of dCK, advancing a novel autoimmune disease treatment.

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...

TORONTO, ON, April 27, 2026 (GLOBE NEWSWIRE) -- Throughout the month of May, MS Canada is calling on Canadians to join in solidarity for MS Awareness Month. On average, someone in Canada is...

Toronto, ON, March 26, 2026 (GLOBE NEWSWIRE) -- This summer, the power of community will meet the thrill of the open road as MS Canada kicks off the 2026 MS Bike season. With a collective...

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter...

Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late...

Toronto, ON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Starting today, the annual MS Read-a-Thon officially kicks off across Canada, challenging young readers to spend the next 30 days (February 9 – March...

PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT ...